&w=3840&q=100)
Can a new project stop flawed medical research before it causes harm?
Sarjna Rai New Delhi
Every day, clinical decisions, health policies, and patient treatments are shaped by scientific studies. But what if those studies are based on manipulated images, skewed data, or biased analysis? What if the medicine you are prescribed was approved based on flawed evidence? These are not just academic questions—they directly affect lives.
Flawed medical research is a growing problem
According to a report published by The Guardian last year, around 10,000 research papers were retracted by journals in 2023.
Watchdog groups like Retraction Watch have tracked the surge in scientific retractions, often issued only after serious flaws or fabrications are uncovered. An analysis by Nature showed a steep rise—from just over 1,000 retractions in 2013 to more than 4,000 in 2022, with numbers crossing 10,000 in 2023 —signalling a deepening credibility crisis in research publishing.
The pandemic accelerated this trend with a spike in pre-prints—scientific papers made public before peer review. While helpful in fast-tracking global knowledge sharing, this also allowed questionable research to bypass scrutiny. Between January 2020 and October 2021, 157 COVID-related papers were retracted, including some from top-tier journals, as reported by The New Indian Express. Notably, high-profile studies on hydroxychloroquine and blood pressure medication in COVID treatment were withdrawn after experts revealed serious data inconsistencies.
In 2016, an inspection of Semler Research's facility in Bengaluru by the US FDA uncovered severe data falsification, including sample manipulation and substitution. The FDA declared the firm's studies unreliable, forcing sponsors to redo trials through alternate agencies. The World Health Organization and European Medicines Agency also took action, highlighting the global reach of flawed data.
What is the Medical Evidence Project trying to do?
The Medical Evidence Project aims to tackle the mounting crisis in research reliability. Funded by a $900,000 grant from Open Philanthropy, the project will focus on identifying manipulated or low-quality studies before they affect patient care or policy.
Led by Boston-based research scientist James Heathers, the initiative will be run under the Centre for Scientific Integrity, the non-profit that also operates Retraction Watch. Heathers will collaborate with Ivan Oransky, the centre's executive director and co-founder of Retraction Watch.
'We originally set up the Centre for Scientific Integrity as a home for Retraction Watch, but we always hoped we would be able to do more in the research accountability space,' Oransky said in a statement. 'The Medical Evidence Project allows us to support critical analysis and disseminate the findings.'
By combining editorial review, forensic screening, and whistleblower tips, the initiative hopes to build a stronger accountability model—preventing both misconduct and honest errors before they influence decisions.
From whistleblowers to watchdogs: How the system will work
The Medical Evidence Project will operate via a dual strategy—combining tip-offs from whistleblowers with systematic screening using digital tools. A core team of up to five investigators will use forensic metascience methods to analyse papers for signs of manipulation, bias, or methodological error. Their findings will be published on Retraction Watch, known for tracking research retractions.
James Heathers described the process in a blog post:
A flaw is identified in a published paper
A detailed report is prepared
If the flaw is serious, it undergoes internal peer review
The findings are then made public
In addition, the project will:
Build software tools to automate parts of the verification process
Follow up on anonymous tips through a dedicated whistleblower channel
Pay external reviewers to independently verify and scrutinise findings
The team aims to uncover at least 10 flawed meta-analyses per year, with the broader goal of raising the reliability of published medical literature.
Why this matters to patients, policymakers, and the public
A study in Misinformation Review by Harvard Kennedy School found that nearly two-thirds of sampled scientific papers on Google Scholar showed signs of being generated using AI tools like GPT. Roughly 14.5 per cent of these flagged studies were health-related—some even appearing in established journals.
The problem is worsened by the fact that Google Scholar does not differentiate between peer-reviewed publications and unvetted content like preprints or student theses. Once flawed studies are cited in meta-analyses or referenced by clinicians, they can misguide patient care, misallocate public funds, and skew health policies.
This is why initiatives like the Medical Evidence Project are vital—not as punitive measures, but as proactive efforts to improve transparency, raise research standards, and restore faith in evidence-based medicine.
Conclusion
Science thrives on credibility. The global push to catch flaws before they become crises marks a pivotal shift in how health research is verified. With ethical oversight, smarter tools, and dedicated investigators, the goal is clear and urgent: to ensure medical evidence truly serves the people who depend on it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
Pharma industry rebuts Siddaramaiah's claims on Covid vax, heart attacks
The Indian pharmaceutical sector strongly rejects Karnataka CM Siddaramaiah's claims that sudden deaths in Hassan district could be linked to Covid vaccines premium Anjali Singh Listen to This Article The Indian pharmaceutical sector strongly rejects Karnataka CM Siddaramaiah's claims that sudden deaths in Hassan district could be linked to Covid vaccines, calling the statements 'misinformed' and harmful to public trust. A day after Karnataka Chief Minister Siddaramaiah linked sudden deaths in the Hassan district to potential side effects of Covid-19 vaccines, the Indian pharmaceutical industry and scientific community strongly countered the claims, calling them 'misinformed' and 'damaging to public trust.' In a post on the social media platform X on July 1, Siddaramaiah stated that more than 20 people had died of heart attacks in Hassan district within a


The Print
an hour ago
- The Print
It looks like a mosquito, flies like one. It's China's newest micro-drone prototype
The bionic microdrone was first displayed on China's state-run military broadcaster, CCTV-7 . 'Here in my hand is a mosquito-like robot,' Liang Hexiang, a student at the NUDT, said on the broadcast. 'Miniature bionic robots like this one are especially suited to information reconnaissance and special missions on the battlefield,' he added. Its wings flap at 500 times per second. Its size makes it almost undetectable by conventional radar systems. It has a stick-thin body, packed heavily with sensors and it is engineered in a way that it looks like a mosquito. New Delhi: It is 2 cm long and weighs 0.3 grams. It has two tiny wings and three spindly legs. No, it's not an insect, but China's new military drone that could change the game of covert warfare forever. Developed in a robotics laboratory at the National University of Defence Technology (NUDT) in central China's Hunan province, the micro-drone can also potentially be used to revolutionise various industries and services. Media reports suggest the micro-drones could be deployed in swarms for warfare and espionage purposes. However, experts say, so far there is no evidence yet that the displayed prototype can be deployed for field operations. China is actively researching swarm technologies to get the micro-drones in action, but has encountered several challenges. One of the biggest challenges is their extremely limited power, sufficient only for indoor flights. The weight and height of the drone, though largely an advantage in stealth operations, do come with payload constraints. Fitting cameras, microphones and communication interceptors is a major engineering challenge. Outdoor use, at this nascent stage, is impractical as even a mild wind can destabilise the micro-drone. At present, the dream of a mosquito-size drone remains restricted to an experimental laboratory. Bryce Barros, a security fellow at the Washington-based Truman National Security Project, told Newsweek: 'The impact of this mosquito-sized drone on wartime surveillance will likely be minimal due to its limited capacity, short range, and presumable short battery life.' Despite the limitations of the mosquito drone, there is speculation that, with modifications, it could see the light of day outside a laboratory. So the potential impact and scope of these nearly invisible surveillance tools is still an exciting prospect. From military reconnaissance to civilian misuse, the purpose of these microdrones lies in the hands of the user. It can infiltrate areas beyond the reach of conventional weapons, while the use of drones for civilian spying and industrial and political espionage cannot be denied. However, its ability to gather information without getting detected presents legal and ethical dilemmas. Timothy Heath, senior defense researcher at the Rand Corporation, told The Telegraph: 'If China is able to produce mosquito-sized drones, it would likely be interested in using them for various intelligence, surveillance and reconnaissance tasks, especially in places that larger drones struggle to access, such as indoor areas.' Other countries too have already sensed the shift in modern warfare technologies and are increasingly exploring miniaturisation. Norway has developed a palm-sized helicopter-style micro-UAV, dubbed the 'Black Hornet', already in use by multiple armed forces, including the US military. The 'Black Hornet' comes with built-in cameras and sensors, controlled by a small handheld unit. In 2019, Harvard scientists published updated research papers of their 'RoboBee' model, which looks very similar to the Chinese microdrone. Some versions of the 'RoboBee' 'transition from swimming underwater to flying' or 'perch on surfaces using static electricity,' according to Harvard's Wyss Institute. It also claimed to build an autonomous UAV that could be used for surveillance to agricultural and environmental monitoring. The current prototype built by NUDT remains a lab demo as China steps into the domain of global micro aerial vehicles, providing a glimpse into a future where warfare and spycraft will not be measured in rockets or tanks but in millimetres. Dedipya Agarwal is an intern who graduated from ThePrint School of Journalism (Edited by Viny Mishra) Also read: Army successfully tests indigenous FPV armed drone like those deployed in Ukraine war


Time of India
2 hours ago
- Time of India
Cancer care startup Onco pulls down shutters as unit economics bite
Academy Empower your mind, elevate your skills Bengaluru-based cancer care Onco has shut its operations, according to Harsh Pokharna, cofounder and chief executive of fintech firm OkCredit, who had invested in Onco in provided online consultancy for cancer patients by being an aggregator platform for hospitals. It also allowed patients to book cancer treatment packages , talk to other patients and get medicines Amit Jotwani, an oncologist, and IIT Kanpur alumnus Rashie Jain founded Onco in 2016. It later got acquired by Apollo Hospitals Group, according to the LinkedIn profiles of the platform had raised over $7 million from top investors, including Accel and Chiratae Ventures, among others, according to Pokharna's LinkedIn post.'They (Onco) also built a strong brand. At their peak, they had 25,000+ visitors and over 1,000 unique leads (cancer patients) every month—all organic, across their website, app, and social channels,' Pokharna said in his post, adding that they thought hospitals would see value in partnering with it. However, it didn't turn out to be so. He further explained the issues that Onco faced in scaling, despite being backed by venture capital firms and investors.'Hospitals in India hold all the power. They don't really need you. Your margins get eaten alive by collections and compliance costs,' he he mentioned that customers don't pay enough for online-only services, and while offline presence is necessary, it is capital-intensive.'Digital is great for leads, but it can't be your whole business. Unit economics just don't work with digital-only solutions because of low ARPU (average revenue per user),' he said. 'Building those offline centres isn't cheap. Each one takes at least 12–24 months to break even.'This development comes at a time when many healthtech startups have entered the segment. Some notable ones include e-pharmacy company PharmEasy, consultation platform Practo, and medicine delivery platform Netmeds, among Jr founder Karan Bajaj's new healthtech startup Complement 1, which focuses on cancer care solutions, raised $16 million in a seed funding round led by global venture capital fund Owl Ventures and early-stage investor Blume Ventures last players are also entering the space. For instance, Tata Digital has entered the e-pharmacy industry through 1mg, which operates through an omnichannel model. Apollo Hospitals also has a similar offering through Apollo Pharmacy.E-commerce giant Amazon is the latest to join the race by expanding its healthcare ambitions, entering the at-home diagnostics market, as it looks to position itself as a comprehensive medical services platform beyond online pharmacy and new startups like instant medicine delivery firm Plazza and instant diagnostics service provider Zet Health in Bengaluru are also trying to disrupt the segment by tapping into the demand for rapid commerce.